Zhejiang Xinkanghe Biopharmaceutical Technology

Zhejiang Xinkanghe Biopharmaceutical Technology is a China-based biotechnology company focused on the research and development of innovative small molecule drugs for metabolic diseases, particularly type 2 diabetes. The company's lead programs include novel GPR119 agonists and SGLT2 inhibitors designed to improve glycemic control and metabolic health. Xinkanghe operates with a focus on high-value chemical drug synthesis and clinical development within the domestic Chinese market. By leveraging its expertise in medicinal chemistry, the company aims to provide more effective and safer therapeutic options for patients with chronic metabolic conditions.